NSABP B-30: Amenorrhea relates to survival

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

In a subset of 2,366 patients from NSABP B-30 with menstrual history available at follow-up, amenorrheic patients (≥ six months) had significantly improved overall and diseasefree survival across treatment arms. Mortality was significantly reduced by 24% and recurrence by 30%.

In a subset of 2,366 patients from NSABP B-30 with menstrual history available at follow-up, amenorrheic patients (≥ six months) had significantly improved overall and diseasefree survival across treatment arms. Mortality was significantly reduced by 24% and recurrence by 30%.

Of 2,111 patients with follow-up quality-of-life data, QOL (by FACT-B rating scale) and symptoms were essentially the same for all regimens at all time points. The exception was the six-month assessment, where patients receiving AC→T had significantly lower QOL and higher symptom scores, but both measurements later returned to baseline (abstract 75). Younger women had more severe symptoms independent of the development of amenorrhea. Persistent amenorrhea was least severe in the AT arm, reported Patricia Ganz, MD, of the University of California, Los Angeles.

“This information about quality of life, symptoms, and amenorrhea risk can be useful in making treatment decisions,” Dr. Ganz said, suggesting AT as an alternative for women in whom preservation of fertility is paramount over the modest improvement in survival.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content